Highlights from the 2022 ASCO gastrointestinal cancer symposium: An overview by the EORTC gastrointestinal tract cancer group.

Recently, we have witnessed impressive diagnostic and therapeutic changes for gastrointestinal cancer patients. New challenges brought by the COVID-19 pandemic have led us to re-evaluate our work priorities. Thanks to the commendable resilience of both investigators and patients, however, clinical research never stopped. In addition to conducting cutting-edge research and serving patients' needs, as EORTC Gastrointestinal Tract Cancer Group, we are committed to pursuing educational initiatives beneficial to the entire European oncology community and beyond. In this regard, we have been providing critical discussions of new data from major international meetings. In this article, we discuss results of important selected studies presented at the 2022 ASCO Gastrointestinal Cancer Symposium, putting them in perspectives and highlighting potential implications for routine practice. With the number of in-person attendees and practice-changing/informing trials presented, this meeting represented a milestone in the return to normality as well as in the fight against cancer.

Informations de copyright

Copyright © 2022 Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest Francesco Sclafani. Consultancy/advisory role and honoraria: AMAL Therapeutics, Bayer, Bristol-Myers Squibb, Dragonfly Therapeutics, Nordic Pharma, Roche. Grants/Research funding: Amgen, AstraZeneca, Bayer, Bristol-Myers Squibb, Roche, Sanofi. Travel grants: Bayer, Lilly. Supported by: La Fondation Contre le Cancer. Elisa Fontana. Employee of Hospital Corporation of America (HCA) International. Anna Dorothea Wagner. Consultancy/advisory role and honoraria: Astellas Pharma, Bristol-Myers Squibb, Daiichi Sankyo, Dragonfly Therapeutics, Merck, Hoffmann-La Roche, Lilly, Pierre Fabre Pharma, Sanofi, Servier. Grants/Research funding: Roche. Juan Valle. Consultancy/advisory role and honoraria: Agios, AstraZeneca, Baxter, Genoscience Pharma, Hutchison Medipharma, Imaging Equipment Ltd (AAA), Incyte, Ipsen, Mundipharma EDO, Mylan, NuCana, QED, Servier, Sirtex, Zymeworks. Grants: NuCana. Elizabeth Smyth. Consultancy/advisory role and honoraria: AMAL Therapeutics, AstraZeneca, Astellas, Beigene, Bristol-Myers Squibb, Celgene, Elsevier, Five Prime Therapeutics, Gritstone Oncology, Merck, Novartis, Pfizer, Roche, Servier, Zymeworks. Grants/Research funding: Bristol-Myers Squibb. Radka Obermannova. Consultancy/advisory role and honoraria: Bristol-Myers Squibb, Merck, MSD, Servier. Grants/Research funding: Roche. Cindy Neuzillet. Consultancy/advisory role and honoraria: Amgen, AstraZeneca, Baxter, Bristol-Myers Squibb, Fresenius Kabi, Incyte Biosciences, Merck, MSD, Mylan, Novartis, Nutricia, Pierre Fabre, Roche, Sanofi, Servier D. Grants/Research funding: AstraZeneca, Fresenius Kabi, Nutricia, OSE Immunotherapeutics, Roche, Servier. Manfred P Lutz. Consultancy/advisory role and honoraria: Servier. Thibaud Koessler. Consultancy/advisory role and honoraria: AMAL Therapeutics, Bayer, Boehringer Ingelheim, Lilly, Merck, MSD, Roche, Vifor. Dirk Arnold. Consultancy/advisory role and honoraria: ACE Oncology, Amgen, Art Tempi Media, Astra Zeneca, Bayer, Boston Scientific, Bristol-Myers Squibb, Personal Aptitude Health, Clinical Care Options (CCO), CRA International, Eli Lilly, Hexal, Imedex, Ipsen, IQVIA, Ketchum, MedAhead, Merck Serono, Merck, Sharp and Dome, PharmaCept, Pierre Fabre Pharma, PRMA Consulting, Roche, Samsung Bioepsis, Sanofi Genzyme, Servier, Streamitup Germany, Tactics MD LLC, Terumo, WebMD Health Corp, Elsevier. Leadership positions: OncoLytics (Project Lead). Maria Alsina. Consultancy/advisory role and honoraria: Amgen, Bristol-Myers Squibb, MSD, Lilly, Servier. Markus Moehler. Consultancy/advisory role and honoraria: Amgen, Bristol-Myers Squibb, Lilly, MCI Group, Merck Serono, MSD, Pfizer, Roche, Taiho. Grants/Research funding: AIO, Amgen, BMBF or HORIZON Europe, Bristol-Myers Squibb, EORTC, German Cancer Aid, Merck Serono, MSD, Pfizer. All conflicts of interest declared by the authors are outside the submitted work. All other authors have declared no conflicts of interest.